Table 6.
Multivariate analysis of overall survival and disease-free survival in 32 patients with primary intrahepatic cholangiocarcinoma.
| Prognostic Factor | Overall Survival | Disease-Free Survival | ||
|---|---|---|---|---|
| HR (95% CI) | p * | HR (95% CI) | p * | |
| Cytoplasmic APEX1 | 1.563 (0.886–2.757) | 0.123 | 1.407 (1.081–1.831) | 0.011 |
| Age at operation | 0.122 | 0.343 | ||
| ≤65 | 1 (reference) | 1 (reference) | ||
| >65 | 0.181 (0.021–1.578) | 0.596 (0.205–1.736) | ||
| Sex | 0.525 | 0.802 | ||
| Male | 1 (reference) | 1 (reference) | ||
| Female | 0.585 (0.112–3.049) | 1.150 (0.385–3.438) | ||
| HBV infection | 0.517 | 0.182 | ||
| No | 1 (reference) | 1 (reference) | ||
| Yes | 0.469 (0.048–4.627) | 0.224 (0.025–2.017) | ||
| Cirrhosis | 0.403 | 0.133 | ||
| No | 1 (reference) | 1 (reference) | ||
| Yes | 3.598 (0.179–72.492) | 5.979 (0.580–61.672) | ||
| Histologic grade | 0.485 | 0.831 | ||
| 1–2 (well and moderate) | 1 (reference) | 1 (reference) | ||
| 3–4 (poorly and undiff.) | 0.459 (0.052–4.073) | 1.145 (0.331–3.966) | ||
| Pathologic stage | 0.787 | 0.718 | ||
| I | 1 (reference) | 1 (reference) | ||
| II–IV | 0.734 (0.078–6.943) | 1.356 (0.260–7.089) | ||
* multivariate Cox regression analysis; HR, hazard ratio; CI, confidence interval; HBV infection, Hepatitis B viral surface antigen (+) and Hepatitis B viral surface antibody (−); and Cytoplasmic APEX1, cytoplasmic expression of APEX1 protein in cancer cells.